Graham Capital Management’s Dyne Therapeutics DYN Stock Holding History

Graham Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Sell	13,172 -22,995	-64%	-$397K	0.01%	900
2025 Q4	$707K	Sell	36,167 -7,009	-16%	-$133K	0.02%	495
2025 Q3	$546K	Buy	43,176 +29,688	+220%	+$339K	0.01%	581
2025 Q2	$128K	Sell	13,488 -48,781	-78%	-$537K	﹤0.01%	1186
2025 Q1	$651K	Buy	+62,269	New	+$891K	0.01%	697
2024 Q3	–	Sell	-6,618	Closed	-$234K	–	1150
2024 Q2	$234K	Sell	6,618 -11,778	-64%	-$342K	0.01%	815
2024 Q1	$522K	Buy	+18,396	New	+$416K	0.01%	616

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Graham Capital Management's DYN Position: Q1 2026 in Review

Graham Capital Management reduced its Dyne Therapeutics (DYN) stake by 64% in Q1 2026, selling an estimated $397K and leaving 13,172 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #900.

Graham Capital Management first reported a position in DYN in Q1 2024 and has held it in 7 quarters since. The position peaked at $707K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Graham Capital Management held 13,172 shares of Dyne Therapeutics worth $239K as of Q1 2026.
Graham Capital Management sold 22,995 Dyne Therapeutics shares in Q1 2026, an estimated $397K.
Dyne Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #900 holding.
Graham Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 7 quarters since.
Graham Capital Management's Dyne Therapeutics position peaked at $707K in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.